Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02559817
Other study ID # LIN-MD-63
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 1, 2015
Est. completion date August 30, 2019

Study information

Verified date December 2020
Source Forest Laboratories
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Patients age 7-11 will receive oral liquid or oral solid capsule and patients 12-17 will receive solid oral capsule formulation. Children ages 7-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks. This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of IBS-C.


Recruitment information / eligibility

Status Terminated
Enrollment 101
Est. completion date August 30, 2019
Est. primary completion date August 30, 2019
Accepts healthy volunteers No
Gender All
Age group 7 Years to 17 Years
Eligibility Inclusion Criteria: - Patient weighs at least 18 kg (39.7 lbs) - Patient meets Rome III criteria for child/adolescent IBS: at least once per week for at least 2 months before Screening Visit, the patient experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time: - a) Improvement with defecation - b) Onset associated with a change in frequency of stool - c) Onset associated with a change in form (appearance) of stool - Patient meets modified Rome III criteria for child/adolescent Functional Constipation (FC): For at least 2 months before the Screening Visit, the patient has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week. In addition, at least once per week, patient meets 1 or more of the following: - a) History of retentive posturing or excessive volitional stool retention - b) History of painful or hard bowel movements (BMs) - c) Presence of a large fecal mass in the rectum - d) History of large diameter stools that may obstruct the toilet - Patient is willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine - Patient has an average of fewer than 3 spontaneous BMs (SBMs) per week during the 14 days before the randomization day and up to the randomization. An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM - Patient or parent/guardian/LAR or caregiver is compliant with eDiary by completing both the morning and evening assessments for 10 out of the 14 days immediately preceding the Randomization Visit Exclusion Criteria: - Patient reports having more than 1 loose, mushy stool (eDiary-recorded stool consistency of 6 on the Pediatric Bristol Stool Form Scale [p-BSFS]) or any watery stool (eDiary-recorded stool consistency of 7 on the p-BSFS) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during the 14 days before the randomization day and up to the randomization - Select medical history or conditions that may be related to other causes of constipation or may interfere with safety and efficacy analyses - Patient has required manual disimpaction anytime prior to randomization or disimpaction during in-patient hospitalization within one year prior to randomization - Patient is unable to tolerate the placebo during rhe Screening Period

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Linaclotide Dose A

Linaclotide Dose B

Linaclotide Dose C

Linaclotide Approved Adult Dose

Matching Placebo


Locations

Country Name City State
Canada Children's Hospital of Western Ontario London Ontario
Canada Physician's Clinical Research Inc. Vaughan Ontario
United States Advanced Research Center - Site 069 Anaheim California
United States Asheboro Research Associates - Site 022 Asheboro North Carolina
United States Children's Center for Digestive Health Care LLC Atlanta Georgia
United States Boys Town National Research Hospital Boys Town Nebraska
United States Coastal Pediatric Research Charleston South Carolina
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Kindred Medical Institute for Clinical Trials, LLC Corona California
United States WCCT Global, LLC Costa Mesa California
United States Ohio Pediatric Research Association Dayton Ohio
United States Cook Children's Medical Center Fort Worth Texas
United States HealthStar Research, LLC Hot Springs Arkansas
United States Houston Clinical Research Associates Houston Texas
United States Texas Children's Hospital/Baylor College Medicine Houston Texas
United States Riley Hospital for Children at Indiana University Health Indianapolis Indiana
United States GI Associates and Endoscopy Center Jackson Mississippi
United States Children's Mercy Hospital Kansas City Missouri
United States Midwest Children Health Research Institute Lincoln Nebraska
United States Midwest Children Health Research Institute Lincoln Nebraska
United States Applied Research Center of Arkansas Little Rock Arkansas
United States ACTCA, Inc Los Angeles California
United States Children's Hospital Los Angeles Los Angeles California
United States Advanced Medical Research Center Miami Florida
United States Goryeb Children's Hospital Morristown New Jersey
United States Coastal Pediatrics Associates Mount Pleasant South Carolina
United States Columbia University Medical Center and Morgan Stanley Children's Hospital of New York New York New York
United States Children's Hospital of The King's Daughters Norfolk Virginia
United States IPS Research Company Oklahoma City Oklahoma
United States Center for Clinical Trials, LLC Paramount California
United States Methodist Medical Center Peoria Illinois
United States St. Christopher's Hospital for Children Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States Preferred Primary Care Physicians, Inc. Pittsburgh Pennsylvania
United States Rhode Island Hospital Providence Rhode Island
United States Capital Pediatrics and Adolescent Center PLLC Raleigh North Carolina
United States Virginia Tech Carilion School of Medicine Pediatric Gastroenterology Roanoke Virginia
United States Sun Research Institute San Antonio Texas
United States University of California at San Francisco San Francisco California
United States Frontier Clinical Research, LLC Scottdale Pennsylvania
United States Willis-Knighton Physician Network Shreveport Louisiana
United States Certified Research Consultants Virgo/Carter Pediatrics Silver Spring Maryland
United States Montgomery Medical Inc. Smithfield Pennsylvania
United States Sleepcare Clinical Research Institute Stockbridge Georgia
United States Aurora Health Care, Aurora Medical Center in Summit Summit Wisconsin
United States MultiCare Institute for Research and Innovation Tacoma Washington
United States ClinPoint Trials Waxahachie Texas
United States Heartland Research Associates, LLC Wichita Kansas

Sponsors (2)

Lead Sponsor Collaborator
Forest Laboratories Ironwood Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Treatment Period SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. SBM rate was defined as SBMs/week during the 4-week Treatment period. Participants recorded the occurrence of BMs and use of rescue medication, morning and evening, daily in an eDiary since pretreatment period. The SBM frequency rate (SBMs/week) during the analysis period for each participant were calculated as [(total number of SBMs in the analysis period/number of days in the analysis period)*7]. Baseline value was based on values collected 14 days before randomization up to randomization. Change from Baseline was calculated as the SBM frequency rate during the 4-week treatment period - SBM frequency rate at baseline. A positive change from Baseline indicates improvement. Baseline (14 days prior to randomization and up to randomization) to week 4
Secondary Change From Baseline in 4-week Abdominal Pain Daytime Symptoms Based on Evening Assessment of Abdominal Pain Symptoms The abdominal pain score was measured using 5-point scale. Participants answered the questions, How much did your tummy hurt as: 0=none, 1=a tiny bit, 2=a little, 3=some, and 4=a lot. The 4-week daytime abdominal pain was calculated as the average of nonmissing scores in evening eDiary during the Treatment Period with higher value indicating greater symptom severity. Baseline value was the average of non-missing values collected 14 days before randomization. Change from Baseline was calculated as the daytime abdominal pain score during the 4-week treatment period (i.e. average of non-missing daytime scores during 4-week treatment period) - daytime abdominal pain score at baseline. A negative change from Baseline indicates improvement. Baseline (14 days prior to randomization) to week 4
Secondary Change From Baseline in 4-week Stool Consistency Participants used 7-point pediatric Bristol Stool Form (p-BSFS) scale to rate stool consistency for each BM in morning and evening eDiary where 1=small hard lumps or balls like pebbles,2=fat sausage shape but lumpy and hard,3=a sausage but with cracks on it,4=sausage or snake, smooth and soft,5=chicken nuggets, soft smooth blobs,6=oatmeal, fluffy mushy pieces,7=milkshake, watery. Scores in 4-week treatment period were calculated as mean of participants non-missing, SBM associated p-BSFS scores during 4-week treatment period. Baseline value was based on values collected 14 days before randomization up to randomization. Baseline (14 days prior to randomization and up to randomization) to week 4
Secondary Change From Baseline in 4-week Severity of Straining Severity of straining was scored on 5-point scale for question-When you pooped, how hard did you push? The score ranges from 0= not hard at all,1= I pushed a tiny bit hard,2= I pushed a little hard,3= I pushed hard,4= I pushed very hard with higher scores indicating more severe straining. Participants recorded degree of straining for each BM in morning and evening eDiary. Scores during 4-week treatment period were calculated as mean of participant's non-missing, SBM associated straining scores during 4-week treatment period. Baseline (14 days prior to randomization and up to randomization) to week 4
Secondary Change From Baseline in 4-week Abdominal Bloating Daytime Symptoms Based on Evening Assessment Participants recorded their assessment of abdominal bloating in the evening eDiary. Participants answered the question: How big and full did your tummy feel? on a scale, where: 0=none, 1=a tiny bit, 2=a little, 3=medium or 4=very, with a higher score indicating more severe bloating. Baseline value was the average of values collected 14 days before randomization. The 4-week daytime abdominal bloating symptoms were calculated as the average of non-missing scores reported in the evening eDiary during the treatment period. Change from Baseline was calculated as the 4-week daytime abdominal bloating score during the treatment period - daytime abdominal bloating score at baseline. A negative change from Baseline indicates improvement. Baseline (14 days prior to randomization) to week 4
Secondary Change From Baseline in 4-week Overall Complete Spontaneous Bowel Movement (CSBM) Frequency Rate (CSBMs Per Week) SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. A CSBM was an SBM that was associated with a sense of complete evacuation. Participants recorded their assessment of the sensation of incomplete evacuation for each BM in the morning and evening eDiary. The 4-week overall CSBM frequency rate was calculated as [total number of CSBMs in the analysis period/number of days in the analysis period]*7). Baseline value was based on values collected 14 days before randomization and up to randomization. Change from Baseline was calculated as the CSBM frequency rate during the 4-week treatment period - CSBM frequency rate at baseline. A positive change from Baseline indicates improvement. Baseline (14 days prior to randomization and up to randomization) to week 4
See also
  Status Clinical Trial Phase
Completed NCT00730171 - An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT00215566 - A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c Phase 2
Completed NCT00765999 - An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT02559206 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Recruiting NCT05646186 - Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome N/A
Completed NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Recruiting NCT05519683 - Home Transcutaneous Electrical Acustimulation (TEA) Phase 2/Phase 3
Active, not recruiting NCT04166058 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase 3
Completed NCT05164861 - Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations N/A
Completed NCT04968652 - IBS-C Questionnaire Study
Completed NCT02590432 - An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Phase 4
Recruiting NCT05796388 - A Study of Virtual Reality and Linaclotide for IBS-C N/A
Completed NCT00380250 - Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT04647045 - An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant N/A
Completed NCT03054506 - The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT04214470 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Not yet recruiting NCT06219707 - Electro-acupuncture for Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT03596905 - Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Completed NCT04132804 - Effect of Tai Chi as Treatment for IBS-C N/A
Completed NCT00938717 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 3